Form 8-K Arcus Biosciences, Inc. For: Oct 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Citi reiterates buy rating on Arcus Biosciences after stock drops 20%
October 21, 2026 4:54 PM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $50.00 price target on Arcus Biosciences (NYSE: RCUS) following a 20% drop in the company's share price.
According to the analyst, the stock's decline was driven in part by a follow-on offering and market expectations that the company's... More



